Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Shire PLC (NASDAQ:SHPG)

184.82
Delayed Data
As of May 25
 -0.53 / -0.29%
Today’s Change
161.09
Today|||52-Week Range
209.22
+8.48%
Year-to-Date
Ultragenyx Receives Priority Review for rhGUS from FDA
May 24 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More
May 19 / Zacks.com - Paid Partner Content
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
May 22 / Zacks.com - Paid Partner Content
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status
May 17 / Zacks.com - Paid Partner Content
Company News for May 19, 2017
May 19 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close185.35
Today’s open184.87
Day’s range183.56 - 185.34
Volume734,593
Average volume (3 months)1,017,658
Market cap$55.9B
Dividend yield0.49%
Data as of 3:59pm ET, 05/25/2017

Growth & Valuation

Earnings growth (last year)-80.61%
Earnings growth (this year)+15.44%
Earnings growth (next 5 years)+14.00%
Revenue growth (last year)+76.71%
P/E ratio131.1
Price/Sales3.89
Price/Book1.90

Competitors

 Today’s
change
Today’s
% change
REGNRegeneron Pharmaceut...-2.54-0.55%
AGNAllergan+0.20+0.09%
ABTAbbott Laboratories+0.42+0.96%
NVONovo Nordisk+0.19+0.46%
Data as of 4:03pm ET, 05/25/2017

Financials

Next reporting dateAugust 2, 2017
EPS forecast (this quarter)$3.58
Annual revenue (last year)$11.3B
Annual profit (last year)$325.1M
Net profit margin5.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Executive Director
Flemming Ornskov
Chief Financial Officer &
Executive Director
Jeffrey Poulton
Corporate headquarters
Dublin, Dublin

Forecasts